0000000000343293

AUTHOR

Paul Perrotte

showing 2 related works from this author

Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell c…

2005

ABSTRACT Purpose: We developed and validated nomograms that accurately predict disease recurrence and progression in patients with Ta, T1, or CIS transitional cell carcinoma (TCC) of the bladder using a large international cohort. Methods: Univariate and multivariate logistic regression models targeted histologically confirmed disease recurrence, and focused on 2,542 patients with bladder TCC from 10 participating centers. Variables consisted of pre-cystoscopy voided urine Nuclear Matrix Protein 22 (NMP22) assay, urine cytology, age and gender. Resulting nomograms were internally validated with bootstrapping. Nomogram performance was explored graphically with Loess smoothing plots. Results:…

AdultMalemedicine.medical_specialtyAdolescentUrologyUrinary systemUrologyurologic and male genital diseasesLogistic regressionBladder neoplasmsnuclear matrix protein 22neoplasm stagingnomogramsBladder NeoplasmCytologyBiomarkers TumormedicineHumansStage (cooking)AgedNeoplasm StagingUrine cytologyAged 80 and overCarcinoma Transitional Cellmedicine.diagnostic_testbusiness.industryNuclear ProteinsMiddle AgedNomogramPrognosismedicine.diseasefemale genital diseases and pregnancy complicationsSurgeryNomogramsTransitional cell carcinomaUrinary Bladder NeoplasmsMultivariate AnalysisDisease ProgressionFemalebusiness
researchProduct

Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma

2008

OBJECTIVE: To assess the value of nuclear matrix protein-22 (NMP22), compared with urinary cytology, in predicting the recurrence of bladder cancer that is not transitional cell carcinoma (non-TCC). PATIENTS AND METHODS: We tested the sensitivity, specificity and the predictive accuracy of NMP22 in the context of non-TCC bladder cancer recurrence, and compared it to the performance of urinary cytology. The study group comprised 2687 patients with history of non-muscle-invasive bladder cancer from 10 centres across four continents. RESULTS: The mean patient age was 64.8 years and 75.4% were men; of all patients, 513 (19.1%) had positive urinary cytology, 906 (33.7%) had a positive NMP22 test…

AdultMalemedicine.medical_specialtyAdolescentUrologyUrinary systemUrologyContext (language use)urologic and male genital diseasesSensitivity and SpecificityCohort StudiesPredictive Value of TestsRisk FactorsCytologyBiomarkers TumormedicineCarcinomaHumansChildAgedRetrospective StudiesAged 80 and overGynecologyBladder cancerbusiness.industryNuclear ProteinsMiddle AgedPrognosismedicine.diseaseTransitional cell carcinomaUrinary Bladder NeoplasmsEpidermoid carcinomaPredictive value of testsCarcinoma Squamous CellFemaleNeoplasm Recurrence LocalbusinessBJU International
researchProduct